Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
Jaguar Health, Inc. announced an additional $3 million payment from Future Pak, LLC after Jaguar terminated a buy-back provision in their U.S. licensing agreement for Mytesi and Canalevia-CA1. This agreement allows Future Pak to continue commercializing these drugs beyond five years, while Jaguar focuses its crofelemer development on human rare-disease intestinal failure indications. Jaguar had previously received $16 million upfront for the initial licensing deal and anticipates further milestone payments.